Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2025-09-05 00:42Core Viewpoint - Heng Rui Medicine has entered into an agreement with Braveheart Bio for the licensing of its innovative drug HRS-1893, which is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [1][2] Group 1: Agreement Details - Heng Rui will grant Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million, which includes a $65 million upfront payment (comprising $32.5 million in cash and $32.5 million in equity) and a $10 million milestone payment upon completion of technology transfer [1] - Heng Rui is eligible for additional milestone payments related to clinical development and sales, potentially reaching up to $1.013 billion [1] Group 2: Drug Information and Strategic Implications - HRS-1893 is a myosin selective inhibitor that reduces left ventricular hypertrophy and improves diastolic relaxation by inhibiting myocardial ATPase activity [2] - The agreement is expected to expand HRS-1893's overseas market presence, providing high-quality treatment options for global patients and enhancing the company's innovative brand and international performance [2] - The company aims to balance independent research and open collaboration, strengthening international partnerships to accelerate the transformation of research outcomes and maximize product value for global patients [2]